文献速递新药、器械与细胞基因治疗研发基础与转化研究

工程化胶囊实现液体mRNA治疗剂口服递送用于临床前肠道疾病治疗

Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease.
PubMed 文献 · Sci Transl Med · 2025-07-16

研究开发了基于胶囊的RNACap装置,用于口服递送液体mRNA纳米颗粒治疗剂至肠道。在大鼠和猪模型中,RNACap在胃内保持完整并在肠道释放内容物,递送mRNA至肠道细胞实现体内转染。在两种大鼠结肠炎模型中,口服负载IL-10 mRNA纳米颗粒的RNACap降低了血液和组织中促炎细胞因子浓度,减轻了结肠炎。

要点

  • RNACap在胃酸性环境中保护mRNA,响应肠道中性pH、胶囊帽溶解压力释放和肠道蠕动而快速释放。
  • 在大鼠和猪模型中,RNACap胃内完整、肠道内释放,猪模型给药后仅8.5小时即见强mRNA表达。
  • 大鼠结肠炎模型中,口服IL-10 mRNA纳米颗粒RNACap降低血和组织促炎细胞因子浓度,减轻结肠炎。

核心结论

  • RNACap是口服递送液体mRNA治疗剂至胃肠道的有前景平台,可用于治疗难治性肠道疾病及潜在其他病症。

研究设计与样本

  • 研究采用工程化胶囊装置RNACap,在大鼠和猪模型中进行体内评价,并在两种大鼠结肠炎模型中验证治疗效应。

主要发现

  • 在大鼠和猪模型中,RNACap在胃内保持完整,在肠道内释放内容物。
  • mRNA纳米颗粒释放后导致多种mRNA的表达。
  • 在两种大鼠结肠炎模型中,口服负载IL-10 mRNA纳米颗粒的RNACap降低了血液和组织中促炎细胞因子浓度,最终减轻结肠炎。
  • 在猪大动物模型中,RNACap在胃内保持完整、在肠道内分解,给药后仅8.5小时即产生强mRNA表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral delivery of messenger RNA (mRNA) therapeutics could offer noninvasive and self-administered treatments and vaccinations. However, the development of oral mRNA therapeutics remains challenging because of the degradative conditions of the gastrointestinal (GI) tract. Here, we engineered a capsule-based device, named RNACap, designed for oral delivery of liquid mRNA nanoparticle (NP) therapeutics to the intestines. RNACap protects mRNA from the acidic stomach environment while allowing rapid release into the intestines in response to intestinal neutral pH, pressure release due to the dissolution of capsule cap, and natural intestinal contractions (peristalsis). This process enables NP-mediated delivery of mRNA into intestinal cells for in vivo transfection. We optimized an NP formulation for rapid intestinal mRNA delivery. In rat and porcine models, we confirmed that the RNACap remains intact in the stomach but releases its contents within the intestines. The release of mRNA NPs led to the expression of multiple mRNAs. The therapeutic effect of the RNACap was demonstrated by acute and delayed treatment in two rat colitis models. Orally administered RNACaps loaded with mRNA encoding interleukin-10 (IL-10 mRNA NP) reduced proinflammatory cytokine concentrations in both blood and tissues, ultimately alleviating colitis. Furthermore, using a large-animal model of swine, we showed that RNACaps remained intact in the stomach, disassembled in the intestine, and resulted in robust mRNA expression just 8.5 hours after administration. RNACap represents a promising platform for the oral delivery of liquid mRNA therapeutics to the GI tract for treating challenging intestinal diseases and potentially other conditions.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Huang X, Liu C, Sharma SN, et al. Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease. Sci Transl Med. 2025. PMID: 40668894. doi:10.1126/scitranslmed.adu1493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。